There was an interesting study that was published recently in Science Magazine. Two researchers at the University of Texas at Austin found a novel regulatory mechanism in cancer cells isolated from an anaplastic large cell lymphoma patient. This discovery could be a beneficial step in treating cancer.
In the study they found a partner protein, ARNT, that interacts with CD30. CD30 is present in high amounts in certain lymphomas. Why is this important? CD30, at high levels, continually activates five cellular proteins which lead to cell proliferation which thus is thought to lead to cancer. The researchers found that ARNT has an ability to shut down CD30 which in turn could shut down the five cellular proteins and this could shut down cell proliferation.
This is an important step in possibly stopping cancerous cells from forming but I must note that it is a very initial discovery but at the same time it is still exciting.
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...